Bulletin
Investor Alert

New York Markets Close in:

Market Pulse Archives

Jan. 20, 2022, 8:42 a.m. EST

NIH says Pfizer's Paxloid should be first treatment option for certain COVID-19 patients

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Pfizer Inc. (PFE)
  • X
    Merck & Co. Inc. (MRK)
  • X
    GlaxoSmithKline PLC ADR (GSK)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

The National Institutes of Health on Wednesday updated its COVID-19 treatment guidelines for patients with mild to moderate forms of COVID-19 who are at high risk for disease progression. The new guidelines now include the recently authorized antivirals developed by Pfizer Inc. /zigman2/quotes/202877789/composite PFE +1.34% and Merck & Co. Inc. /zigman2/quotes/209956077/composite MRK +0.74% /Ridgeback Biotherapeutics, note that GlaxoSmithKline /zigman2/quotes/209463850/composite GSK +0.76% and Vir Biotechnology Inc.'s /zigman2/quotes/214486077/composite VIR +3.37% sotrovimab is the only monoclonal antibody that is thought to be effective against omicron, and have added a three-day course of Gilead Sciences Inc.'s /zigman2/quotes/210293917/composite GILD +1.40% Veklury as a treatment option. The panel suggests that clinicians first use Pfizer's Paxlovid, then sotrovimab, then Veklury, and the final option should be molnupiravir, which is the Merck/Ridgeback drug.

/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 51.35
+0.68 +1.34%
Volume: 16.16M
May 17, 2022 3:55p
P/E Ratio
11.75
Dividend Yield
3.13%
Market Cap
$286.17 billion
Rev. per Employee
$1.17M
loading...
/zigman2/quotes/209956077/composite
US : U.S.: NYSE
$ 93.00
+0.68 +0.74%
Volume: 14.01M
May 17, 2022 3:55p
P/E Ratio
16.62
Dividend Yield
2.97%
Market Cap
$233.46 billion
Rev. per Employee
$799,500
loading...
/zigman2/quotes/209463850/composite
US : U.S.: NYSE
$ 44.71
+0.34 +0.76%
Volume: 2.91M
May 17, 2022 3:55p
P/E Ratio
16.22
Dividend Yield
4.47%
Market Cap
$111.50 billion
Rev. per Employee
$552,510
loading...
/zigman2/quotes/214486077/composite
US : U.S.: Nasdaq
$ 23.03
+0.75 +3.37%
Volume: 324,367
May 17, 2022 3:55p
P/E Ratio
2.53
Dividend Yield
N/A
Market Cap
$2.95 billion
Rev. per Employee
$5.24M
loading...
/zigman2/quotes/210293917/composite
US : U.S.: Nasdaq
$ 63.11
+0.87 +1.40%
Volume: 3.94M
May 17, 2022 3:55p
P/E Ratio
17.60
Dividend Yield
4.63%
Market Cap
$78.07 billion
Rev. per Employee
$1.91M
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.